Form 4: Director Todd Davis Increases Stake in Pelthos Therapeutics

Director Todd Davis purchased 35,948 shares of Pelthos Therapeutics common stock in open market transactions.

Summary

• Director Todd C. Davis acquired a total of 35,948 shares of Pelthos Therapeutics Inc. (PTHS) common stock on June 11, 2026.
• The purchases were executed in two tranches: 35,445 shares at a weighted average price of $27.8046 and 503 shares at a weighted average price of $28.7261.
• Following these transactions, Mr. Davis directly owns 75,834 shares of the company.
• Mr. Davis also maintains an indirect interest in 1,500,000 shares held by Ligand Pharmaceuticals Incorporated, where he serves as CEO and board member.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as open-market purchases by a director typically indicate confidence in the company's future performance.

Positives

• Insider confidence is demonstrated by the director's decision to increase his personal equity stake in the company.
• The purchase was made at market prices, signaling alignment between management and shareholder interests.

Negatives

• None identified in this filing.

Risks

• The reporting person may be deemed to have beneficial ownership of shares held by Ligand Pharmaceuticals, which could create potential conflicts of interest or regulatory reporting complexities.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this disclosure.

Industry Context

StockSavvy.ai notes that insider buying is generally viewed as a bullish signal by the market, suggesting that leadership believes the current share price does not fully reflect the company's long-term value or growth prospects.

Comparison to Industry Standards

• Insider buying activity is consistent with standard corporate governance practices where directors demonstrate 'skin in the game' to align with shareholder interests.

Related Party Transactions

• The filing notes that Todd Davis is the CEO and a director of Ligand Pharmaceuticals, which holds 1,500,000 shares of Pelthos Therapeutics.

Stakeholder Impact

• Shareholders may interpret the director's purchase as a vote of confidence in the company's current valuation and strategic direction.

Key Dates

Keywords

Pelthos Therapeutics, PTHS, Insider Trading, Form 4, Equity Ownership, Todd Davis